Analysis of anti-tumor-effects of ?d T cells on cancer cells
Recruiting
- Conditions
- C96.9Malignant neoplasm of lymphoid, haematopoietic and related tissue, unspecified
- Registration Number
- DRKS00033100
- Lead Sponsor
- Klinikum Nürnberg - Hämatologie/Onkologie
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 125
Inclusion Criteria
Healthy donors:
- Written consent
Patients with haematological neoplasms:
- Written consent
- Medical indication for sampling
Exclusion Criteria
Healthy donors:
- current illness
- Previous donation for the same (sub-)project
- Previous donation within the last 3 months
Patients with haematological neoplasms:
- unreasonable burden by additional sampling
- assumed risk by additional sampling
- delay of clinical diagnostics or therapy by study inclusion
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The aim of the study is to optimise the anti-cancer-effect of ?d T cells against malignant cells for a future clinical use. This includes the effector function of ?d T cells with a focus on the cytotoxicity against cancer cells as well as the in vitro expansion and stimulation of ?d T cells. After the stimulation, the effectiveness of ?d T cells is measured in in vitro assays against cancer cell lines and cancer cells, which are isolated from patient blood. We aim to increase the effectiveness of ?d T cells by adjusting the experimental conditions and the addition of therapeutically substances.
- Secondary Outcome Measures
Name Time Method